Clinical Trials Logo

Clinical Trial Summary

Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: - To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. - To relate proteomic findings to survival data - To identify potential serum markers of breast cancer progression


Clinical Trial Description

This is a translational study. Patient will undergo standard treatment and tissue and blood samples will be taken at various time points: Tissue: Fresh frozen (FF) and Formalin fixed paraffin embedded tissue (FFPE) will be collected at time of surgery/biopsy of a primary or a recurrent/metastatic tumour tissue. Blood: Two types of study bloods (non-heparinised and Ethylenediaminetetraacetic acid (EDTA)) will be taken pre-neoadjuvant treatment (if applicable), pre- and post-operatively of primary and recurrent/ metastatic breast cancer (if recurrent/metastatic diagnosis and no biopsy/surgery required then study bloods will be taken prior to starting treatment). Additional blood samples will be taken annually at follow-up visits for 5 years from primary cases and for up to 2 years from recurrent/metastatic cases. Non-heparinised blood will be processed to serum. Clinical data will be collected at all times of biological sampling. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01840293
Study type Observational
Source Cancer Trials Ireland
Contact
Status Recruiting
Phase
Start date February 2013
Completion date January 2038

See also
  Status Clinical Trial Phase
Recruiting NCT05923177 - Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 Phase 1
Completed NCT01033162 - Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care N/A
Recruiting NCT03270007 - Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy Phase 4
Completed NCT00527449 - Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel Phase 2
Completed NCT04468113 - Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
Recruiting NCT03711877 - Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) Phase 3
Active, not recruiting NCT01019616 - Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy Phase 3
Completed NCT01314833 - Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Phase 3
Completed NCT04127019 - Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) Phase 3
Terminated NCT00172068 - Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow Phase 2
Completed NCT01049425 - Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Phase 3
Completed NCT01779479 - Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Phase 2
Completed NCT04277338 - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 Phase 1
Recruiting NCT05445050 - mULM to Support Breast Cancer Diagnosis and Therapy N/A
Completed NCT00793377 - Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer Phase 3